SOURCE: MMIT Analytics, as of 8/20/19
Thursday, August 22, 2019
Harmony Biosciences last week won its...
...first-ever FDA approval for its
narcolepsy drug Wakix. The drug will be a direct competitor to Jazz
Pharmaceuticals' Xyrem, which currently holds preferred status in the pharmacy
benefit for 11% of covered lives, growing to 23% with prior authorization
and/or step therapy.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment